Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deric L Wheeler

Showing results (41-50 of 72) with videos related to

Pageof 8
Sort By:
Nano Letters|June 9, 2020
An Avidity-Based PD-L1 Antagonist Using Nanoparticle-Antibody Conjugates for Enhanced ImmunotherapyJiyoon Bu, Ashita Nair, Mari Iida, et al.
Cancer Research|November 3, 2004
Protein kinase C epsilon is an endogenous photosensitizer that enhances ultraviolet radiation-induced cutaneous damage and development of squamous cell carcinomasDeric L Wheeler, Kaitlin E Martin, Kristin J Ness, et al.
Molecular Cancer|October 26, 2014
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapyMari Iida, Toni M Brand, Megan M Starr, et al.
Neoplasia (New York, N.Y.)|November 9, 2013
Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximabMari Iida, Toni M Brand, Megan M Starr, et al.
BMC Cancer|April 24, 2022
AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancerMari Iida, Nellie K McDaniel, Kourtney L Kostecki, et al.
BMC Cancer|October 11, 2012
Activation of AKT by hypoxia: a potential target for hypoxic tumors of the head and neckHanneke Stegeman, Johannes H Kaanders, Deric L Wheeler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2010
Augmentation of radiation response by motesanib, a multikinase inhibitor that targets vascular endothelial growth factor receptorsTim J Kruser, Deric L Wheeler, Eric A Armstrong, et al.
Cell Death & Disease|January 7, 2018
Anti-Trop2 blockade enhances the therapeutic efficacy of ErbB3 inhibition in head and neck squamous cell carcinomaNathan Redlich, Anthony M Robinson, Kwangok P Nickel, et al.
Molecular Cancer Therapeutics|March 18, 2014
Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancerToni M Brand, Mari Iida, Emily F Dunn, et al.
Cancer Research|August 20, 2014
AXL mediates resistance to cetuximab therapyToni M Brand, Mari Iida, Andrew P Stein, et al.
Pageof 8

Showing results (41-50 of 72) with videos related to

Sort By:
Pageof 8
Nano Letters|June 9, 2020
An Avidity-Based PD-L1 Antagonist Using Nanoparticle-Antibody Conjugates for Enhanced ImmunotherapyJiyoon Bu, Ashita Nair, Mari Iida, et al.
Cancer Research|November 3, 2004
Protein kinase C epsilon is an endogenous photosensitizer that enhances ultraviolet radiation-induced cutaneous damage and development of squamous cell carcinomasDeric L Wheeler, Kaitlin E Martin, Kristin J Ness, et al.
Molecular Cancer|October 26, 2014
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapyMari Iida, Toni M Brand, Megan M Starr, et al.
Neoplasia (New York, N.Y.)|November 9, 2013
Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximabMari Iida, Toni M Brand, Megan M Starr, et al.
BMC Cancer|April 24, 2022
AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancerMari Iida, Nellie K McDaniel, Kourtney L Kostecki, et al.
BMC Cancer|October 11, 2012
Activation of AKT by hypoxia: a potential target for hypoxic tumors of the head and neckHanneke Stegeman, Johannes H Kaanders, Deric L Wheeler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2010
Augmentation of radiation response by motesanib, a multikinase inhibitor that targets vascular endothelial growth factor receptorsTim J Kruser, Deric L Wheeler, Eric A Armstrong, et al.
Cell Death & Disease|January 7, 2018
Anti-Trop2 blockade enhances the therapeutic efficacy of ErbB3 inhibition in head and neck squamous cell carcinomaNathan Redlich, Anthony M Robinson, Kwangok P Nickel, et al.
Molecular Cancer Therapeutics|March 18, 2014
Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancerToni M Brand, Mari Iida, Emily F Dunn, et al.
Cancer Research|August 20, 2014
AXL mediates resistance to cetuximab therapyToni M Brand, Mari Iida, Andrew P Stein, et al.
Pageof 8